Facebook: World Allergy Organization
Twitter: World Allergy Organization
LinkedIn: World Allergy Organization
Back to Top

Welcome World Allergy Forum: Geneva, Switzerland

Ruby Pawankar Cezmi Akdis

Dear Colleagues,

A warm welcome to the forty-second symposium in the World Allergy Forum (WAF) series: Eosinophilia and Co-morbid Conditions. Recognizing the importance of Eosinophilia, the World Allergy Organization (WAO) is delighted to bring this symposium to the 2012 Annual EAACI Congress in Geneva, Switzerland. WAO is proud and appreciative that this symposium is an annual event at the Congress, with the EAACI hosting the World Allergy Forum every year since this major educational program commenced fifteen years ago and continues as a sign of very long term collaboration with the EAACI.

WAO is proud to announce that the year 2012 marks the 15th anniversary of the World Allergy Forum. The first WAF was presented at the AAAAI Annual Meeting in San Francisco in 1997 and WAO is appreciative that this symposium is an annual event at the AAAAI Annual Meeting. Since 1997, WAF has flourished and become the longest continuing educational program of World Allergy Organization (WAO).

The eosinophil is an often misunderstood cell - it plays a central role in defense against parasitic infections, but when present in excess numbers, it may cause significant disease and disability. This WAF Symposium will address the eosinophil and the disorders of this interesting blood cell. Today’s symposium is composed of world renowned experts on this subject. Prof. Hans-Uwe Simon will review current concepts in the pathogenesis of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. Dr. Marc Rothenberg will discuss the recent advances in understanding the intrinsic (genetic) and extrinsic (environmental) components and the key molecular pathways and antigenic triggers that illustrate the complex nature of this emerging disease. Dr. Amy Klion will conclude today’s symposium by examining hypereosinophilic syndrome. There will be an open discussion following the formal lectures.

The WAO Board hopes that you enjoy today’s program with its wealth of information which can be used in your everyday clinical practice. If you would like to access the faculty materials after the session they will be available at:

WAO gratefully acknowledges the unrestricted educational grant from Novartis that supports educations programs such as this conjoint program at the EAACI meeting.

With best regards,

Symposium Chairs

Ruby Pawankar, MD, PhD, FAAAAI
President, World Allergy Organization

Cezmi Akdis, MD
President, European Academy of Allergy and Clinical Immunology